Systemic treatment of malignant mesothelioma

R.M. Rudd

Source: Eur Respir Mon; 2009: 44: 419–434
Journal Issue: Thoracic Malignancies
Disease area: Thoracic oncology

PDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
R.M. Rudd. Systemic treatment of malignant mesothelioma. Eur Respir Mon; 2009: 44: 419–434

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Systemic therapy 1 in malignant pleural mesothelioma: chemotherapy
Source: ERS Online Course 2020: Calendar sheets in malignant pleural diseases
Year: 2020

Second-line chemotherapy in malignant pleural mesothelioma (MPM)
Source: Eur Respir J 2002; 20: Suppl. 38, 273s
Year: 2002

Malignant pleural mesothelioma: new treatment modalities
Source: Annual Congress 2005 - Clinical year in review
Year: 2005

Systemic therapy 2 in malignant pleural mesothelioma: immuno- & targeted therapy
Source: ERS Online Course 2020: Calendar sheets in malignant pleural diseases
Year: 2020

Chemotherapy for treatment of malignant pleural mesothelioma
Source: Eur Respir J 2004; 24: Suppl. 48, 526s
Year: 2004

Systemic treatment of malignant pleural effusion
Source: Annual Congress 2005 - What's new in the pleura
Year: 2005


Treatment of malignant pleural mesothelioma with combination of carboplatin, caelyx, and gemzitabine: the CCG study of the Nordic mesothelioma group
Source: Eur Respir J 2004; 24: Suppl. 48, 526s
Year: 2004

Multimodal therapy in malignant pleural mesothelioma (MPM)
Source: Eur Respir J 2002; 20: Suppl. 38, 187s
Year: 2002

Polychemotherapy experience in pleural mesothelioma with or without pemetrexed
Source: Annual Congress 2009 - Pleural and mediastinal diseases
Year: 2009


Comparison between treatment with IL2, and IL2 in combination with chemotherapy in malignant pleural mesothelioma
Source: Annual Congress 2009 - Pleural and mediastinal diseases
Year: 2009


Treatment of malignant pleural mesothelioma with caelyx: few responses but good survival
Source: Eur Respir J 2004; 24: Suppl. 48, 526s
Year: 2004

Surgery and multimodality treatment for malignant pleural mesothelioma
Source: Eur Respir Mon; 2009: 44: 407–418
Year: 2009

Bevacizumab-targeted therapy for malignant pleural mesothelioma
Source: International Congress 2017 – Malignant pleural effusion management in 2017: a review of recent RCTs
Year: 2017


Efficacy of pleurodesis for malignant pleural effusions in breast cancer patients
Source: Eur Respir J 2011; 38: 1425-1430
Year: 2011



Evaluation of response to chemotherapy for malignant pleural mesothelioma and suggestion of a new method
Source: Eur Respir J 2002; 20: Suppl. 38, 272s
Year: 2002

Efficacious pleurodesis with OK-432 and doxorubicin against malignant pleural effusions
Source: Eur Respir J 2004; 24: 263-266
Year: 2004



Is there any advantage of chemotherapy on survival of patients with diffuse malignant pleural mesothelioma?
Source: Eur Respir J 2003; 22: Suppl. 45, 29s
Year: 2003

Multimodality therapy for malignant pleural mesothelioma
Source: Eur Respir J 2004; 24: Suppl. 48, 526s
Year: 2004

Intrapleural photodynamic therapy for malignant pleural mesothelioma: A new dosimetry approach
Source: International Congress 2016 – Mesothelioma and malignant pleural disease
Year: 2016


Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed
Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases
Year: 2010